Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingcheng Guo

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)Chenguang Wang, Chaoxin Zhou, Sheng Hou, et al.
Mabs|January 14, 2016
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacyYun Yang, Qingcheng Guo, Xi Chen, et al.
Analytical Biochemistry|September 14, 2021
N-Glycosylation and enzymatic activity of the rHuPH20 expressed in Chinese hamster ovary cellsTao Liu, Yantao Li, Jin Xu, et al.
Mabs|November 29, 2017
Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responsesBoning Liu, Huaizu Guo, Jin Xu, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 28, 2022
Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteinsTao Liu, Yantao Li, Jin Xu, et al.
Mabs|April 7, 2016
Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cellsYantao Li, Tuo Fu, Tao Liu, et al.
Mabs|June 17, 2016
Acid-induced aggregation propensity of nivolumab is dependent on the FcBoning Liu, Huaizu Guo, Jin Xu, et al.
Biochemical and Biophysical Research Communications|October 11, 2016
Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancerXi Chen, Jin Xu, Qingcheng Guo, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 2, 2025
Longitudinal profiling of cerebrospinal fluid N-glycome dynamics in glioblastoma patients treated with apatinibTao Liu, Yiru Kong, Xiaoyu Ji, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2024
Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibodyRongrong Fu, Jin Xu, Qingcheng Guo, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)Chenguang Wang, Chaoxin Zhou, Sheng Hou, et al.
Mabs|January 14, 2016
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacyYun Yang, Qingcheng Guo, Xi Chen, et al.
Analytical Biochemistry|September 14, 2021
N-Glycosylation and enzymatic activity of the rHuPH20 expressed in Chinese hamster ovary cellsTao Liu, Yantao Li, Jin Xu, et al.
Mabs|November 29, 2017
Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responsesBoning Liu, Huaizu Guo, Jin Xu, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 28, 2022
Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteinsTao Liu, Yantao Li, Jin Xu, et al.
Mabs|April 7, 2016
Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cellsYantao Li, Tuo Fu, Tao Liu, et al.
Mabs|June 17, 2016
Acid-induced aggregation propensity of nivolumab is dependent on the FcBoning Liu, Huaizu Guo, Jin Xu, et al.
Biochemical and Biophysical Research Communications|October 11, 2016
Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancerXi Chen, Jin Xu, Qingcheng Guo, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 2, 2025
Longitudinal profiling of cerebrospinal fluid N-glycome dynamics in glioblastoma patients treated with apatinibTao Liu, Yiru Kong, Xiaoyu Ji, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2024
Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibodyRongrong Fu, Jin Xu, Qingcheng Guo, et al.
Pageof 3